Esperion To Grant 75,000 Shares To 18 New Employees
ANN ARBOR—Esperion Therapeutics Inc., a developer of a new class of cholesterol-reducing drugs, announced that the compensation committee of its board of directors granted non-qualified stock options to purchase an aggregate of 39,500 shares of its common stock and 35,388 restricted stock units (RSUs) to 18 new employees under Esperion’s 2017 Inducement Equity Incentive Plan.